Denmark’s Novo Nordisk has signed a collaboration with Boston-based Vivtex Corporation to develop next-generation oral biologic medicines for obesity, diabetes and associated metabolic diseases. Vivtex is eligible to receive upfront payments, research funding and milestone payments totalling up to $2.1 billion (approximately €1.78bn), as well as tiered royalties on net sales of any resulting products.
Lilly’s triple weight loss combination therapy retatrutide has shown 28.7% weight loss in Phase 3, but higher discontinuations vs. tirzepatide and semaglutide.
Novo Nordisk is to acquire US-based Akero Therapeutics in a US$5.2 billion deal aimed at reviving growth and entering the MASH-space where others like Roche and GSK have recently expanded their footprint.
Eli Lilly, the US market leader in the lucrative diabetes and obesity space, is now challenging its competitor Novo Nordisk in the area of oral GLP-1 receptor agonists. Lilly’s orforglipron has met the primary endpoint of its registration study and is set to be submitted for approval in the United States.
MC2 Therapeutics A/S, a Hørsholm-based pharmaceutical company focused on topical therapies in inflammatory skin conditions, announced the appointment of Trine Ahlgreen as Chief Executive Officer at the end of May.
The FDA has approved Novo Nordisk’s blockbuster drug Ozempic (semaglutide) for patients with chronic kidney disease who also have type 2 diabetes.
Novo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing a once-monthly GLP-1 receptor agonist.
In both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity blockbuster.
Novo Nordisk realises a major expansion in Clayton, NC (USA). The project will enhance Novo Nordisk’s manufacturing capabilities with more than 1.4 million square feet of new space.
A German-Danish team has discovered that a truncated version of the enzyme adenlyate cyclase 3 can be targeted to transform fat-storing white adipocytes into fat-burning brown adipocytes.
Momoneymoproblemz - wikimedia
Novo Nordisk
Adobe stock photos - Jim
MC2 Therapeutics A/S
Bild von freepik
Novo Nordisk
By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038